|Printable version||E-mail this to a friend|
Cancer Research UK - Precision medicine trial first of its kind to show benefit to patients
A clinical trial for types of advanced cancer is the first of its kind to show that precision medicine – or tailoring treatment for individual people – can slow down the time it takes for a tumour to grow back, according to research presented at the Molecular Analysis for Personalised Therapy (MAP) conference(link is external), last week.
Results from the trial, which took place at the Gustave Roussy Cancer Campus(link is external) in Paris, found that 199 out of 1110 patients with advanced cancer, who had their genes mapped and their treatment tailored, had around 30 per cent longer before their cancer started growing again compared to any of the previous therapies the patients had tried. This ranged from between five and 32 months.
This trial involved patients who had no other treatment options left and who had already tried three or more cancer therapies. The team found potential faulty molecules to target for 411 of these patients and experimental drugs to hit the targets for 199 of these patients.
The patients on this trial had diverse types of advanced cancer including lung, breast, head and neck, prostate, bladder, bowel and stomach cancer.
The MAP conference is a joint initiative between Cancer Research UK, UNICANCER and ESMO.
Professor Jean Charles Soria, principal investigator of the trial from the Gustave Roussy Cancer Campus, said: “This is the first precision medicine trial to show that analysing a person’s DNA improves treatment options for patients with late stage cancer. And these results are particularly exciting because in some cases we were testing experimental drugs, and found that we could slow down the growth of tumours in around one in five patients with advanced cancer.”
Dr Christophe Massard, head of the early drug development multidisciplinary committee at Gustave Roussy, said: “The great thing about this is that it’s not just for one type of cancer - patients with many different types of cancer could benefit from this in the future.”
Dr Rowena Sharpe, head of precision medicine at Cancer Research UK, said: “This is an exciting time for precision medicine and personalised treatment. It’s fantastic to see continued effort going into this area and it’s important that we make the most of the data that we already have. The MAP meeting brings together expertise from across the globe to find the best ways to improve precision medicine programmes for cancer patients.”
For media enquiries please contact the Cancer Research UK press office on +44 203 469 8300 or, out-of-hours, the duty press officer on +44 7050 264 059.
Notes to Editor
The clinical trial is called MOSCATO 01
Latest News from
Age UK - 'Squalor and distress' - life for older people in private rented housing27/10/2016 12:35:00
An Age UK report has revealed the reality of life for people over 65 at the bottom of the private rented sector.
BHF - Study finds oxidants aren't always bad for the heart27/10/2016 11:40:00
Scientists funded by BHF have discovered that oxidants, which have historically been blamed for heart disease, have a vital role ensuring the heart pumps blood around the body effectively.
Cancer Research UK - Researchers deploy viruses to improve cancer treatments26/10/2016 09:35:00
STAND UP TO CANCER-funded researchers are using viruses to ramp up the effectiveness of a range of cancer treatments – including immunotherapy and radiotherapy, in a new study launched this month.
BHF - Long-term exposure to air pollution and traffic noise effects blood pressure25/10/2016 15:35:00
Long-term exposure to air pollution is linked to a greater incidence of high blood pressure, according to the largest study to investigate the effects of both air pollution and traffic noise.
Age UK - Older people who pay their own way in care homes struggling to get a ‘fair deal’20/10/2016 13:35:00
Two in five (41%) residents in UK independent care homes are now paying for their own care - an increase of almost a third (28.5%) in the last 10 years (from 130,000 in 2005 to167,000 in 2014). This rise is a result of the state-funded system declining while demand from our ageing population continues to rise.